FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890941407> ?p ?o ?g. }

• W2890941407 endingPage "22" @default.
• W2890941407 startingPage "11" @default.
• W2890941407 abstract "Drug-fortified cationic liposomes of 6‑methoxy‑2‑naphthylacetic acid (6‑MNA) were prepared and characterized by various techniques. The residence time of drug-fortified liposomes in joint cavity was evaluated by intra-articular (IA) administration of the radio-labeled (99mTc) liposomal formulation in the inflamed joints in rats. The cationic liposomal formulation composed of 6‑MNA (3) as an active agent, its double salt (4) with the lipid 1,2‑distearoyl‑sn‑glycero‑3‑phosphoethanolamine (DSPE), and pharmaceutically acceptable excipients such as hydrogenated soyabean phospatidylcholine (HSPC) and 1,2‑dioleyloxy‑3‑trimethylammoniumpropane chloride (DOTAP) were developed using thin film hydration technique. The cryo-TEM analysis confirmed that the prepared optimized liposomal formulation (DFL-2) was a mixture of small unilamellar vesicles (SUVs), large unilamellar vesicles (LUVs) and multilamellar vesicles (MLVs). In addition, the TEM analysis confirmed that the prepared liposomes were of spherical in shape having liposome size in the range of 500-900 nm and zeta potential of about +30 mV. The developed cationic liposomes exhibited sustained release profile of payload of 6‑MNA for over >12 h and about five times higher retention in the inflamed animal joints after 24 h (by scintigraphy of the joints) as compared to the plain 6‑MNA solution when administered by IA route. The anti-inflammatory activity of prepared liposomal composition is evaluated by Freund's adjuvant induced arthritic model in rats. The liposomal formulation was well tolerated by all animals indicating good biocompatibility. Further, the cationic liposomal formulation treated group showed decreased erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) level in comparison to the control and the standard groups in the in vivo study. The improved efficacy of the drug-fortified liposomal formulation was due to the coupled effect of longer retention and sustained release of the active drug 6‑MNA in the joints. From the obtained results it could be concluded that the combined effect of the cationic charge on the drug-fortified liposomes and the inherent affinity of the active agent towards the synovial joint tissues, coupled with slow release of the active drug due to double salt approach at the site of administration could potentially decrease the frequency of IA drug administration. Hence such a formulation could prove to be a therapeutic boon for the management of late stage arthritis." @default.
• W2890941407 created "2018-09-27" @default.
• W2890941407 creator A5011973371 @default.
• W2890941407 creator A5022699290 @default.
• W2890941407 creator A5030681596 @default.
• W2890941407 creator A5040039930 @default.
• W2890941407 creator A5042425492 @default.
• W2890941407 creator A5057367389 @default.
• W2890941407 creator A5057409261 @default.
• W2890941407 date "2018-12-01" @default.
• W2890941407 modified "2023-10-16" @default.
• W2890941407 title "Drug-fortified liposomes as carriers for sustained release of NSAIDs: The concept and its validation in the animal model for the treatment of arthritis" @default.
• W2890941407 cites W181315115 @default.
• W2890941407 cites W1971659341 @default.
• W2890941407 cites W1975916494 @default.
• W2890941407 cites W1990325109 @default.
• W2890941407 cites W2002054331 @default.
• W2890941407 cites W2002164057 @default.
• W2890941407 cites W2015227877 @default.
• W2890941407 cites W2019598869 @default.
• W2890941407 cites W2032507536 @default.
• W2890941407 cites W2033829451 @default.
• W2890941407 cites W2041349928 @default.
• W2890941407 cites W2043575440 @default.
• W2890941407 cites W2047520267 @default.
• W2890941407 cites W2052425219 @default.
• W2890941407 cites W2053729182 @default.
• W2890941407 cites W2055319262 @default.
• W2890941407 cites W2057083263 @default.
• W2890941407 cites W2065455355 @default.
• W2890941407 cites W2070353556 @default.
• W2890941407 cites W2078979823 @default.
• W2890941407 cites W2082235510 @default.
• W2890941407 cites W2083288589 @default.
• W2890941407 cites W2099716233 @default.
• W2890941407 cites W2146038109 @default.
• W2890941407 cites W2146294830 @default.
• W2890941407 cites W2147912854 @default.
• W2890941407 cites W2159842188 @default.
• W2890941407 cites W2161836547 @default.
• W2890941407 cites W2226428821 @default.
• W2890941407 cites W2434649883 @default.
• W2890941407 cites W2553192808 @default.
• W2890941407 cites W2616167388 @default.
• W2890941407 cites W2621741705 @default.
• W2890941407 cites W2728075768 @default.
• W2890941407 doi "https://doi.org/10.1016/j.ejps.2018.09.009" @default.
• W2890941407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30219410" @default.
• W2890941407 hasPublicationYear "2018" @default.
• W2890941407 type Work @default.
• W2890941407 sameAs 2890941407 @default.
• W2890941407 citedByCount "11" @default.
• W2890941407 countsByYear W28909414072019 @default.
• W2890941407 countsByYear W28909414072020 @default.
• W2890941407 countsByYear W28909414072021 @default.
• W2890941407 countsByYear W28909414072022 @default.
• W2890941407 countsByYear W28909414072023 @default.
• W2890941407 crossrefType "journal-article" @default.
• W2890941407 hasAuthorship W2890941407A5011973371 @default.
• W2890941407 hasAuthorship W2890941407A5022699290 @default.
• W2890941407 hasAuthorship W2890941407A5030681596 @default.
• W2890941407 hasAuthorship W2890941407A5040039930 @default.
• W2890941407 hasAuthorship W2890941407A5042425492 @default.
• W2890941407 hasAuthorship W2890941407A5057367389 @default.
• W2890941407 hasAuthorship W2890941407A5057409261 @default.
• W2890941407 hasConcept C104317684 @default.
• W2890941407 hasConcept C111599444 @default.
• W2890941407 hasConcept C130316041 @default.
• W2890941407 hasConcept C13245373 @default.
• W2890941407 hasConcept C155672457 @default.
• W2890941407 hasConcept C155887181 @default.
• W2890941407 hasConcept C171250308 @default.
• W2890941407 hasConcept C178790620 @default.
• W2890941407 hasConcept C183882617 @default.
• W2890941407 hasConcept C185154212 @default.
• W2890941407 hasConcept C185592680 @default.
• W2890941407 hasConcept C192562407 @default.
• W2890941407 hasConcept C2779820397 @default.
• W2890941407 hasConcept C41625074 @default.
• W2890941407 hasConcept C43617362 @default.
• W2890941407 hasConcept C55493867 @default.
• W2890941407 hasConcept C71924100 @default.
• W2890941407 hasConcept C86181022 @default.
• W2890941407 hasConcept C98274493 @default.
• W2890941407 hasConceptScore W2890941407C104317684 @default.
• W2890941407 hasConceptScore W2890941407C111599444 @default.
• W2890941407 hasConceptScore W2890941407C130316041 @default.
• W2890941407 hasConceptScore W2890941407C13245373 @default.
• W2890941407 hasConceptScore W2890941407C155672457 @default.
• W2890941407 hasConceptScore W2890941407C155887181 @default.
• W2890941407 hasConceptScore W2890941407C171250308 @default.
• W2890941407 hasConceptScore W2890941407C178790620 @default.
• W2890941407 hasConceptScore W2890941407C183882617 @default.
• W2890941407 hasConceptScore W2890941407C185154212 @default.
• W2890941407 hasConceptScore W2890941407C185592680 @default.
• W2890941407 hasConceptScore W2890941407C192562407 @default.
• W2890941407 hasConceptScore W2890941407C2779820397 @default.
• W2890941407 hasConceptScore W2890941407C41625074 @default.

• next